Voyager Therapeutics, Inc. (VYGR)
Chart Events
Performance Outlook
| Previous Close | 6.48 |
| Open | 6.47 |
| Bid | 6.32 x 1100 |
| Ask | 6.90 x 1400 |
| Day's Range | 6.36 - 6.47 |
| 52 Week Range | 2.46 - 10.60 |
| Volume | |
| Avg. Volume | 247,301 |
| Market Cap | 241.409M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cross species transduction for multiple capsids and characterization of the receptor for a leading capsid support human translation potential of TRACERTM capsids Catherine J. Mackey, Ph.D., appointed to Board of Directors Strong ba
- GlobeNewswire
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
Novel passive antibodies bind to paired helical filamentous tau and inhibit propagation of pathological tau Vectorized antibody demonstrates durable CNS expression more than six months post-dose Research presented at the Alzheimer’s Association International Conference CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, t
- GlobeNewswire
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate u
